Logo image of UTHR

UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis

USA - NASDAQ:UTHR - US91307C1027 - Common Stock

422.01 USD
-0.52 (-0.12%)
Last: 10/22/2025, 12:30:06 PM
Fundamental Rating

7

Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 534 industry peers in the Biotechnology industry. UTHR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. UTHR is valued quite cheap, while showing a decent growth score. This is a good combination! This makes UTHR very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year UTHR was profitable.
In the past year UTHR had a positive cash flow from operations.
Each year in the past 5 years UTHR has been profitable.
Each year in the past 5 years UTHR had a positive operating cash flow.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

UTHR's Return On Assets of 15.71% is amongst the best of the industry. UTHR outperforms 96.07% of its industry peers.
Looking at the Return On Equity, with a value of 17.31%, UTHR belongs to the top of the industry, outperforming 95.13% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 16.17%, UTHR belongs to the top of the industry, outperforming 96.44% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for UTHR is in line with the industry average of 15.49%.
The last Return On Invested Capital (16.17%) for UTHR is above the 3 year average (14.96%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 15.71%
ROE 17.31%
ROIC 16.17%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

UTHR's Profit Margin of 40.36% is amongst the best of the industry. UTHR outperforms 97.94% of its industry peers.
UTHR's Profit Margin has improved in the last couple of years.
UTHR's Operating Margin of 50.06% is amongst the best of the industry. UTHR outperforms 99.63% of its industry peers.
In the last couple of years the Operating Margin of UTHR has grown nicely.
The Gross Margin of UTHR (88.98%) is better than 90.26% of its industry peers.
In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 50.06%
PM (TTM) 40.36%
GM 88.98%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTHR is still creating some value.
Compared to 1 year ago, UTHR has less shares outstanding
The number of shares outstanding for UTHR has been increased compared to 5 years ago.
UTHR has a better debt/assets ratio than last year.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 18.54 indicates that UTHR is not in any danger for bankruptcy at the moment.
The Altman-Z score of UTHR (18.54) is better than 89.70% of its industry peers.
There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 18.54
ROIC/WACC1.72
WACC9.38%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

UTHR has a Current Ratio of 7.26. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
UTHR has a Current ratio of 7.26. This is in the better half of the industry: UTHR outperforms 70.41% of its industry peers.
UTHR has a Quick Ratio of 6.94. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
UTHR has a Quick ratio of 6.94. This is in the better half of the industry: UTHR outperforms 69.10% of its industry peers.
Industry RankSector Rank
Current Ratio 7.26
Quick Ratio 6.94
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

6

3. Growth

3.1 Past

UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.74%, which is quite good.
The Earnings Per Share has been growing by 16.88% on average over the past years. This is quite good.
The Revenue has grown by 17.62% in the past year. This is quite good.
UTHR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.71% yearly.
EPS 1Y (TTM)17.74%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%9.57%
Revenue 1Y (TTM)17.62%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%11.71%

3.2 Future

UTHR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.54% yearly.
Based on estimates for the next years, UTHR will show a quite strong growth in Revenue. The Revenue will grow by 10.10% on average per year.
EPS Next Y14.09%
EPS Next 2Y8.76%
EPS Next 3Y5.24%
EPS Next 5Y13.54%
Revenue Next Year11.6%
Revenue Next 2Y8.62%
Revenue Next 3Y7.44%
Revenue Next 5Y10.1%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30 40 50

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 16.47 indicates a correct valuation of UTHR.
Based on the Price/Earnings ratio, UTHR is valued cheaply inside the industry as 96.07% of the companies are valued more expensively.
UTHR's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.77.
The Price/Forward Earnings ratio is 14.50, which indicates a correct valuation of UTHR.
UTHR's Price/Forward Earnings ratio is rather cheap when compared to the industry. UTHR is cheaper than 95.13% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.23. UTHR is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.47
Fwd PE 14.5
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

UTHR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. UTHR is cheaper than 96.82% of the companies in the same industry.
UTHR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. UTHR is cheaper than 95.32% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.82
EV/EBITDA 9.01
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of UTHR may justify a higher PE ratio.
PEG (NY)1.17
PEG (5Y)0.98
EPS Next 2Y8.76%
EPS Next 3Y5.24%

More info and screens

0

5. Dividend

5.1 Amount

UTHR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (10/22/2025, 12:30:06 PM)

422.01

-0.52 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-29 2025-10-29/amc
Inst Owners99.47%
Inst Owner Change-0.5%
Ins Owners1.76%
Ins Owner Change4.02%
Market Cap19.09B
Revenue(TTM)3.08B
Net Income(TTM)1.24B
Analysts80.91
Price Target489.79 (16.06%)
Short Float %6.27%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.95%
Min EPS beat(2)-9.46%
Max EPS beat(2)-0.45%
EPS beat(4)0
Avg EPS beat(4)-4.06%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)3
Avg EPS beat(8)-1.6%
EPS beat(12)6
Avg EPS beat(12)-0.99%
EPS beat(16)7
Avg EPS beat(16)-3.25%
Revenue beat(2)1
Avg Revenue beat(2)2.03%
Min Revenue beat(2)-2.65%
Max Revenue beat(2)6.71%
Revenue beat(4)2
Avg Revenue beat(4)0.97%
Min Revenue beat(4)-2.65%
Max Revenue beat(4)6.71%
Revenue beat(8)6
Avg Revenue beat(8)2.26%
Revenue beat(12)8
Avg Revenue beat(12)1.8%
Revenue beat(16)10
Avg Revenue beat(16)1.71%
PT rev (1m)3.6%
PT rev (3m)26.06%
EPS NQ rev (1m)-1.04%
EPS NQ rev (3m)-2.36%
EPS NY rev (1m)1.31%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-2.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE 16.47
Fwd PE 14.5
P/S 6.2
P/FCF 17.82
P/OCF 13.92
P/B 2.66
P/tB 2.7
EV/EBITDA 9.01
EPS(TTM)25.62
EY6.07%
EPS(NY)29.1
Fwd EY6.89%
FCF(TTM)23.68
FCFY5.61%
OCF(TTM)30.32
OCFY7.18%
SpS68.05
BVpS158.6
TBVpS156.14
PEG (NY)1.17
PEG (5Y)0.98
Graham Number302.37
Profitability
Industry RankSector Rank
ROA 15.71%
ROE 17.31%
ROCE 20.88%
ROIC 16.17%
ROICexc 27.55%
ROICexgc 28.28%
OM 50.06%
PM (TTM) 40.36%
GM 88.98%
FCFM 34.8%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 376.79%
Cap/Sales 9.76%
Interest Coverage 58.37
Cash Conversion 84.62%
Profit Quality 86.22%
Current Ratio 7.26
Quick Ratio 6.94
Altman-Z 18.54
F-Score6
WACC9.38%
ROIC/WACC1.72
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)17.74%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%9.57%
EPS Next Y14.09%
EPS Next 2Y8.76%
EPS Next 3Y5.24%
EPS Next 5Y13.54%
Revenue 1Y (TTM)17.62%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%11.71%
Revenue Next Year11.6%
Revenue Next 2Y8.62%
Revenue Next 3Y7.44%
Revenue Next 5Y10.1%
EBIT growth 1Y21.63%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year18.1%
EBIT Next 3Y5.05%
EBIT Next 5Y-4.6%
FCF growth 1Y59%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y58%
OCF growth 3Y30.42%
OCF growth 5YN/A